Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Multiple Cancer Types
The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF / ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).
Leukemia,
Myelodysplastic Syndrome,
Phase I
I/II
Byrne, Michael
NCT02152956
VICCHEMP1828
